公开(公告)号：US20210015824A1

公开(公告)日：2021-01-21

申请号：US16978563

申请日：2019-03-08

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Hong LIU ,  Jia LI ,  Jiang WANG ,  Yi ZANG ,  Jian LI ,  Jingya LI ,  Dandan SUN ,  Hualiang JIANG ,  Kaixian CHEN

IPC: A61K31/5377 ,  A61K31/519 ,  A61P1/16

Abstract: Disclosed is use of a thieno[3,2-d]pyrimidin-4-one compound represented by general formula (I). Definition of each substituent is as stated in the description and claims, and the compound is used for preparing medicines for treating and/or preventing liver fibrosis and related diseases or preparing a DPP-4 inhibitor, or is used as a DPP-4 inhibitor.

公开(公告)号：US20190276453A1

公开(公告)日：2019-09-12

申请号：US16420140

申请日：2019-05-22

Applicant: Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. ,  Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Inventor： Xibin LIAO ,  Jia LI ,  Zhijian LU ,  Yubo ZHOU ,  Anhui GAO

IPC: C07D471/04 ,  C07D403/04

Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):

公开(公告)号：US20190100507A1

公开(公告)日：2019-04-04

申请号：US16085311

申请日：2017-03-16

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Hong LIU ,  Jia LI ,  Jiang WANG ,  Mingbo SU ,  Shuni WANG ,  Yubo ZHOU ,  Wei ZHU ,  Wei XU ,  Chunpu LI ,  Hualiang JIANG ,  Kaixian CHEN

IPC: C07D401/12 ,  C07D401/06 ,  C07D405/12 ,  C07D409/12 ,  C07D409/14 ,  C07D409/06 ,  C07D417/12 ,  C07D471/04 ,  C07D205/04 ,  C07D265/30 ,  C07D211/38 ,  C07D211/96 ,  A61P35/00

Abstract: Provided is a fluorinated cyclopropylamine compound represented by formula I, a racemate thereof, an R-isomer thereof, an S-isomer thereof, a pharmaceutical salt thereof, and a mixture thereof. Also provided are pharmaceutical compositions containing the compound, a preparation method for the compound, and uses thereof as a lysine specific demethylase 1 (LSD1) inhibitor, and in the treatment of cancers.

公开(公告)号：US20230357244A1

公开(公告)日：2023-11-09

申请号：US18029359

申请日：2021-09-28

Applicant: Shanghai Institute of Materia Medica, Chinese Academy of Sciences

Inventor： Huaqiang XU ,  Jia LI ,  Jingjing SHI ,  Yi ZANG ,  Dandan SUN ,  Mingliang LIU ,  Rongrong XIE ,  Erli YOU ,  Lixin GAO ,  Qian TAN

IPC: C07D471/08

CPC classification number: C07D471/08

Abstract: A strong FXR small-molecule agonist, and a preparation method therefor and use thereof, the structure of the agonist being represented by formula (I), are provided. In the formula, each substituent is as defined in the description and the claims. The compound provided has the advantages of high FXR agonist activity, simple synthesis, easily available raw materials and the like, and can be used for preparing medicines for treating FXR related diseases.

公开(公告)号：US20190211005A1

公开(公告)日：2019-07-11

申请号：US16329336

申请日：2017-08-24

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Fajun NAN ,  Jia LI ,  Jian DING ,  Meiyu GENG ,  Yangming ZHANG ,  Yi CHEN ,  Yubo ZHOU ,  Chaojun GONG ,  Mingbo SU ,  Anhui GAO

IPC: C07D417/04 ,  A61P35/02

Abstract: The invention describes an aryl-2,2′-tandem bisthiazole compound and a preparation method and the use thereof. In particular, disclosed in the present invention are an aryl-2,2′-tandem bisthiazole compound with the structure as shown in general formula I and the preparation method thereof and use thereof as a histone deacetylase inhibitor in the preparation of antitumor drugs.

公开(公告)号：US20180305390A1

公开(公告)日：2018-10-25

申请号：US15738675

申请日：2016-06-23

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Hong LIU ,  Jia LI ,  Jiang WANG ,  Jingya LI ,  Hui CHEN ,  Dan LI ,  Jian LI ,  Yibing WANG ,  Hualiang JIANG ,  Kaixian CHEN

IPC: C07H19/01 ,  A61P3/08

CPC classification number: C07H19/01 ,  A61K31/35 ,  A61K31/381 ,  A61K31/427 ,  A61K31/4436 ,  A61P3/08 ,  C07D493/10

Abstract: C, O-spiro aryl glycoside compounds are provided. Specifically provided are C, O-spiro aryl glycoside compounds represented by the formula (I), wherein the definitions of each variable group are described in the specification. Also provided are methods of preparing and using the C, O-spiro aryl glycoside compounds. The C, O-spiro aryl glycoside compounds can be used as SGLT2 inhibitors and for treating diseases, such as diabetes, atherosclerosis, and adiposity.

公开(公告)号：US20180222904A1

公开(公告)日：2018-08-09

申请号：US15763095

申请日：2016-10-03

Applicant: Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. ,  SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Xibin LIAO ,  Jia LI ,  Zhijian LU ,  Yubo ZHOU ,  Anhui GAO

IPC: C07D471/04 ,  A61K45/06 ,  A61K31/437 ,  A61K31/56 ,  A61K31/4545 ,  A61K31/5377 ,  A61K31/501 ,  A61K31/519 ,  A61K31/42

CPC classification number: C07D471/04 ,  A61K31/4184 ,  A61K31/42 ,  A61K31/437 ,  A61K31/4545 ,  A61K31/501 ,  A61K31/519 ,  A61K31/52 ,  A61K31/5377 ,  A61K31/56 ,  A61K45/06 ,  A61P29/00 ,  A61P35/00 ,  C07D235/22 ,  C07D473/34 ,  C07D487/04

Abstract: Bruton's tyrosine kinase (Btk) inhibitors have the following Formula (I):

公开(公告)号：US20240270753A1

公开(公告)日：2024-08-15

申请号：US18560605

申请日：2022-03-30

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Bing ZHOU ,  Jia LI ,  Yubo ZHOU ,  Xiangbo YANG ,  Bo FENG ,  Yaxi YANG ,  Xiaobei HU

IPC: C07D491/107 ,  A61K31/497 ,  A61K31/5025 ,  C07D519/00

CPC classification number: C07D491/107 ,  A61K31/497 ,  A61K31/5025 ,  C07D519/00

Abstract: The present invention relates to a heterocyclic compound for inhibiting SHP2 activity that is represented by formula I, a preparation method therefor and use thereof. The compound of the present invention is effective in treating a disease or disorder or condition mediated by SHP2.

公开(公告)号：US20190039989A1

公开(公告)日：2019-02-07

申请号：US16075528

申请日：2017-02-20

Applicant: SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Fajun NAN ,  Jia LI ,  Jingya LI ,  Mei ZHANG ,  Zhifu XIE ,  Jingtao WANG ,  Dongdong GUO

IPC: C07C61/35 ,  C07C57/13 ,  C07C57/26

CPC classification number: C07C61/35 ,  A61K31/194 ,  C07C55/28 ,  C07C57/13 ,  C07C57/26 ,  C07C57/42 ,  C07C61/16 ,  C07C61/20 ,  C07C61/22 ,  C07C2601/08 ,  C07C2601/16 ,  Y02P20/55

Abstract: The present invention relates to a class of fatty acid compounds, a preparation method thereof and use thereof. The fatty acid compounds have the structure of the formula I, which has the ability to activate APMK and inhibit the glucose output in mouse primary hepatocytes. The fatty acid compounds can be used in preparing a medicament for the treatment of obesity or diabetes.

公开(公告)号：US20170107213A1

公开(公告)日：2017-04-20

申请号：US15128298

申请日：2015-03-21

Applicant: ZHEJIANG UNIVERSITY ,  SHANGHAI INSTITUTE OF MATERIA MEDICA, CHINESE ACADEMY OF SCIENCES

Inventor： Xiaowu DONG ,  Jia LI ,  Bo YANG ,  Yongzhou HU ,  Yubo ZHOU ,  Qinjie WENG ,  Wenhu ZHAN ,  Lei XU ,  Tao LIU ,  Qiaojun HE

IPC: C07D417/14 ,  C07D401/12 ,  C07D409/14 ,  C07D413/14 ,  C07D405/14 ,  C07D401/14

CPC classification number: C07D417/14 ,  C07D401/12 ,  C07D401/14 ,  C07D405/14 ,  C07D409/14 ,  C07D413/14

Abstract: Disclosed are new substituted nitrogen-containing heterocyclic derivatives represented by formula (I) as AKT inhibitors, optical isomers, pharmaceutically acceptable salts or solvates thereof, wherein the definition of R1, R2, R3, R4, R5, R6, ring A, ring C, B, Q, Y, Z and m is shown in the description for details. In addition, medicaments comprising the derivatives as active components are also disclosed, which can be useful for treating proliferative diseases, such as cancer and inflammation, especially diseases relating to AKT kinase.